Altre lingue Percheron Therapeutics Limited

Azioni

PER

AU0000317281

Prezzo di chiusura Australian S.E. Altri mercati azionari 00:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,068 ^AUD	+6,25%		-6,85%	+15,25%

28/02	Percheron Therapeutics Limited riporta i risultati degli utili per il semestre conclusosi il 31 dicembre 2023	CI
2023	Antisense Therapeutics lancia uno strumento di vendita di azioni per i pacchi non commercializzabili	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Dimerix Appoints Nonexecutive Chair	20/11
Antisense Therapeutics Limited has Changed its Name to Percheron Therapeutics Limited	15/11
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels	09/10/23
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23
Antisense Therapeutics' Share Purchase Plan Raises AU$3.3 Million	21/08/23
Antisense Therapeutics Appoints CEO/Managing Director	07/08/23
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023	07/08/23
Antisense Therapeutics Limited Announces Management Changes	07/08/23
Antisense Therapeutics to Launch Share Purchase Plan; Shares Plunge 8%	20/07/23
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK	27/06/23
Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%	08/06/23
Antisense Therapeutics Appoints CEO/Managing Director	08/05/23
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023	08/05/23
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director	08/05/23
Antisense Therapeutics Begins Dosing in Toxicology Study for Muscular Dystrophy Treatment	14/03/23
Antisense Therapeutics Limited Announces the Commencement of Dosing in the Nine-Month Chronic Monkey Toxicology Study of ATL1102	13/03/23
Antisense Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/02/23
Antisense Therapeutics Secures Turkish Clearance for Phase 2 Muscular Dystrophy Trial	14/02/23
Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency	13/02/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Percheron Therapeutics Limited

Azioni

PER

AU0000317281

Altre lingue

Filtri